Refractory Osteomyelitis Caused by *Mycobacterium aubagnense* and Its L-Form: Case Report and Review of the Literature

Jianghao Cheng, Long Zhang, Qian Huang, Chaodan Li, Jianhua Yu, Mingli Zhu

Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China

Correspondence: Mingli Zhu, Email mlzhhz@163.com

**Purpose:** To report a rare case of tibial osteomyelitis caused by *Mycobacterium aubagnense* and its L-form, to systematically review non-tuberculous mycobacteria (NTM) infections of the bones, and to summarize the medication guidelines for infections with NTM and its L-forms.

**Methods:** Case report and literature review.

**Results:** We report a 31-year-old HIV-positive man who developed osteomyelitis caused by *M. aubagnense* and its L-form. Culture, electron microscopy, polymerase chain reaction assay, and a reversion test confirmed the existence of *M. aubagnense*. The patient was treated with surgical debridement and a combination of systemic antibiotics, and continued to take antiretroviral treatment. Some clinical improvement was noted shortly after the initiation of this treatment. Resolution of osteomyelitis was achieved after 10 months. We also systematically reviewed cases of NTM osteomyelitis in the PubMed database and compared antibiotic sensitivity between L-forms and their prototype bacteria. We have summarized the treatment regimens for infections of the bone and bone marrow caused by NTM and their L-forms.

**Conclusion:** We have reported the first case of refractory osteomyelitis caused by *M. aubagnense* and its L-form in a patient with immune deficiency, reviewed the literature on NTM osteomyelitis, and compared the antibiotic sensitivity of L-forms and their prototype bacteria.

**Keywords:** non-tuberculous mycobacteria, HIV, bone and bone marrow infection

**Introduction**

Osteomyelitis refers to the infectious inflammation of the bones and bone marrow. Its etiology mainly includes bloodstream infection, traumatic infection, blood circulation disorder, and low host immune function. Almost all microorganisms, including viruses, bacteria, and fungi, can cause osteomyelitis. Many pathogens such as *Staphylococcus aureus*, *Salmonella*, *Candida*, non-tuberculous mycobacteria (NTM), *Cryptococcus*, *Bartonella*, and *Mycobacterium tuberculosis* have been reported to cause osteomyelitis. NTM have recently garnered increased research attention because they can cause infections in immunocompromised patients, in whom, the infection presents as a disseminated extrapulmonary form. Compared to tuberculosis (TB), NTM infections must be treated for a much longer duration.

L-form bacteria are cell wall-deficient bacteria that are produced by bacterial mutation; these forms can be induced experimentally in many bacterial species by treatment with antibiotics, lytic enzymes, and/or certain amino acids that interfere with the bacterial cell wall or its synthesis. In one study, *Mycobacterium bovis* was reported to produce L-form variants under stress conditions, suggesting that NTM can easily transform into L-forms under the influence of antibiotics and other factors. L-forms can also revert to their prior state, albeit at a low frequency. L-form bacteria need to grow and reproduce in a hypertonic environment, so their successful culture requires special culture conditions, and considerable skill and experience, or these variants are quite easy to miss. Thus far, no cases of osteomyelitis caused by *Mycobacterium aubagnense* and its L-form have been reported. In this study, we report a case of tibial osteomyelitis caused by *M. aubagnense* and its L-form that was successfully managed using surgical debridement and antibiotic therapy for 10 months. The present case highlights the importance of considering NTM and their L-forms, when investigating chronic, relapsing osteomyelitis. We also conducted a literature review considering NTM and their L-forms, when investigating chronic, relapsing osteomyelitis. We also conducted a literature review...
of cases of NTM osteomyelitis, and compared the antibiotic sensitivities of L-forms and their prototype bacteria. We concluded that appropriate pharmacotherapy along with surgical debridement is the optimal method to treat NTM osteomyelitis and avoid relapses. We advise that clinicians remain vigilant when evaluating uncommon forms of osteomyelitis.

Case Report
A 31-year-old man presented to our outpatient clinic with redness, swelling, and severe pain in both knees as well as an inability to walk since one year ago. The patient who had been HIV positive for 7 years had a history of severe prurigo nodularis for four years and had tubercle bacillus bloodstream infection two years ago. His antiretroviral treatment was successful. He did not have any relevant family history or history of genetic diseases. After admission, the patient underwent bilateral curettage for tibial osteomyelitis under epidural anesthesia. An anterior incision was made at the proximal end of the tibia. Bone destruction was observed at up to a depth of approximately 2 cm inside the tibial tubercle, and a large amount of purulent secretion was discharged from the anterior tibial incision. The inflammatory granulation tissue and scar tissue were removed. A small curette was used to eliminate the inflammatory granulation tissues and pus in the remaining dead space, and the removed material was placed in a sterile bag. Bone cement was used to fill in the tibial defect, and the wound surface was covered with VSD dressing and fixed on the peripheral skin. Continuous vacuum aspiration was performed to drain the wound (Figure 1). Culture of the wound drainage fluid showed no growth of mycobacteria or other bacteria after 1 week, but a small number of red acid-fast positive spheroids were detected on smear microscopy (Figure 2). Considering that the patient had a history of tuberculous bloodstream infection and had symptoms of low fever and fatigue, we initially suspected a diagnosis of tuberculous osteomyelitis. The patient was immediately administered anti-multidrug-resistant tuberculosis (MDR-TB) treatment, but the response was not good. After 21 days of culture, no *M. tuberculosis* growth was observed, and the Xpert MTB/RIF and T-SPOT.TB tests were negative, indicating that there was no TB infection and explaining the patient’s lack of response to the anti-MDR-TB treatment. As some red acid-fast spheroids had been observed on microscopy, we now considered the possibility of infection with the L-forms of *M. tuberculosis* or NTM. Culture, microscopic examination, electron microscopy (Figure 3), polymerase chain reaction (PCR) assays and a reversion test (Figure 4) confirmed the presence of NTM and its L-forms. The patient was therefore treated with moxifloxacin, prothionamide, linezolid, isoniazid, rifampicin, and
Figure 2 Microscopic morphology (400 x) of L-form NTM. (red spheroids, arrows).

Figure 3 Morphology of L-form NTM (blue arrows) on electron microscopy.

Figure 4 Acid-fast bacilli, slightly curved, with a tendency to branch (arrows) are observed on microscopy after the reversion test.
ethambutol for 10 months, according to the results of the drug-sensitivity test. After this treatment, the wounds appeared clean, with no evidence of redness, swelling, heat, or pain. Thus, amputation of the affected legs was avoided.

**Discussion**

Disseminated NTM infection has been a major cause of mortality and comorbidity in patients with human immunodeficiency virus (HIV) infection. Osteomyelitis is commonly caused by *S. aureus* and *M. tuberculosis*; NTM osteomyelitis is quite rare, and is usually observed following trauma. Thus far, there have been no reports about osteomyelitis caused by *M. aubagnense* and its L-form in patients with acquired immunodeficiency syndrome (AIDS).

NTM include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. *Mycobacteroides abscessus*, *Mycobacterium avium* complex (MAC), *Mycobacterium malmoense*, and *Mycobacterium xenopi* are clinically the most important species. According to a survey released by the CDC in the United States, the incidence rate of NTM infections (per 100,000 persons) was 1.8 during 1981–1983, which increased to 9.1 in 1997 and 14.1 in 2003, and has reached 17.7 according to recent data. This indicates that the incidence and prevalence of NTM infections are increasing. NTM infections most commonly present as pulmonary infections (5.6 per 100,000 persons), followed by skin and soft-tissue infections (0.9 per 100,000), and rarely cause osteomyelitis (0.3 per 100,000 persons).

One of the most important predisposing factors for NTM infection is an immunocompromised state, such as that seen in patients with HIV infection, those using immunosuppressive agents, those with mutations related to the interleukin-12 (IL-12)–interferon gamma (IFN-γ) axis, and those with hematological malignancies. In the US, approximately 43% of AIDS patients had disseminated NTM infections in the pre-anti-retroviral therapy era. MAC are the most common species isolated from patients with systemic immunosuppression and NTM infection. A recent study reported that the prevalence of mycobacterial disease in patients with interferon gamma receptor 1 (IFN-γR1) deficiency was 95%, and that MAC was the most commonly isolated mycobacterial pathogen from these patients. The mean prevalence of NTM infections in patients with hematological malignancies is 1.2%, which is far higher than the prevalence in the normal population. This suggests that NTM may be an opportunistic infection in patients with hematological malignancies.

Invasive infections caused by NTM have included lymphatic, skin, bone, and soft-tissue infections in addition to pulmonary involvement. NTM infections are common among individuals with immunodeficiency, diabetes, or alcohol addiction. To better assess the clinical presentation of NTM osteomyelitis and its relevance, we studied the main causative agents, diagnostic tools, treatment options, and treatment duration after diagnosis among patients with NTM osteomyelitis. We searched the PubMed database for reports of NTM osteomyelitis published between 1995 and August 2022 and assessed the full texts of the retrieved papers for relevance and eligibility.

The pooled data provided that 21 cases reports (Table 1). The mean age of the 21 patients was 52 ± 22.8 years and 52.4% of the reported cases occurred in male patients. The NTM infection sites among the 21 patients were as follows: vertebrae, 10 patients; clavicle, 3 patients; tibia, ankle, femur, and fibula, 2 patients each; and frontal bone, wrist, elbow, metacarpal, skull, and sternum, 1 patient each. Five patients had multiple infection site. The following pathogenic microorganisms were identified: MAC, 4 patients; *Mycobacteroides abscessus*, 3 patients; *Mycobacteroides chelonae* infections and *Mycobacterium riadhense*, 2 patients each; and *Mycobacterium monacense*, *Mycobacterium farrigenes*, *Mycobacterium phlei*, *Mycobacterium haemophilum*, *Mycobacterium fortuitum*, *Mycobacterium kansasii*, *Mycobacterium goodii*, *Mycobacterium flavescens*, *Mycobacterium avium*, and *Mycobacterium senegalense*, 1 patient each. Vertebral osteomyelitis caused by NTM is more common among immunosuppressed patients than among immunocompetent patients, and was found in 5 of 7 (71.4%) patients with various degrees of immunosuppression in our review. Trauma, including fracture, burns, dermatosis, and impact injury, is one of the most important causes of NTM infection. In our study, many patients (36.4%) developed NTM infection of the tibia or other skeletal sites after surgery or trauma. In all patients, the diagnostic work-up involved imaging methods, and culture, biopsy, and molecular biology methods were essential for identifying the pathogen. Once NTM osteomyelitis is diagnosed, surgical debridement is the most effective treatment. Adjunctive surgical therapy with debridement was reported in most of the cases in our review (81.0%), with obvious clinical improvement. In addition, individualized antimycobacterial chemotherapy is also essential for treatment. The 4 most commonly used drugs in our review were clarithromycin (42.9%), amikacin (28.6%),...
<table>
<thead>
<tr>
<th>Study</th>
<th>Age/ Sex</th>
<th>Pathogen</th>
<th>Underlying Condition</th>
<th>Position</th>
<th>Diagnosis Tools</th>
<th>Antibiotics</th>
<th>Surgical Treatment</th>
<th>Length of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashraf et al</td>
<td>70/M</td>
<td><em>M. monacense</em></td>
<td>Diabetes</td>
<td>Vertebra</td>
<td>MRI, Culture, PCR</td>
<td>FOX, CIP, CLARY, IPM, LZD, MXF</td>
<td>Yes</td>
<td>11 months</td>
</tr>
<tr>
<td>Farsi et al</td>
<td>49/M</td>
<td><em>M. farcinogenes</em></td>
<td>Operation</td>
<td>Tibia</td>
<td>MRI, Culture, MALDI-TOF, PCR</td>
<td>CIP, CLARY</td>
<td>Yes</td>
<td>6 months</td>
</tr>
<tr>
<td>Saad et al</td>
<td>24/F</td>
<td><em>M. riyadhense</em></td>
<td>None</td>
<td>Vertebra</td>
<td>MRI, Biopsy, Culture, PCR</td>
<td>AZT, RFP, INH, PZD</td>
<td>No</td>
<td>13 months</td>
</tr>
<tr>
<td>Saad et al</td>
<td>18/F</td>
<td><em>M. riyadhense</em></td>
<td>None</td>
<td>Frontal bone</td>
<td>MRI, Culture, PCR</td>
<td>MXF, INH, RFP, EMB</td>
<td>Yes</td>
<td>6 months</td>
</tr>
<tr>
<td>McGee et al</td>
<td>45/M</td>
<td><em>M. phlei</em></td>
<td>Operation</td>
<td>Vertebra</td>
<td>MRI, Culture, Biopsy</td>
<td>VAN, AZM, MIN</td>
<td>Yes</td>
<td>12 months</td>
</tr>
<tr>
<td>Gray et al</td>
<td>70/F</td>
<td><em>MAC</em></td>
<td>Immunosuppression</td>
<td>Vertebra</td>
<td>CT, Biopsy, DHT</td>
<td>AZT, EMB</td>
<td>Yes</td>
<td>12 months</td>
</tr>
<tr>
<td>Moral et al</td>
<td>82/M</td>
<td><em>M. abscessus</em></td>
<td>Cataclasis</td>
<td>Vertebra</td>
<td>MRI, Culture, Biopsy, PCR</td>
<td>AMK, AZT, MEM</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Elsayed et al</td>
<td>56/F</td>
<td><em>M. haemophilum</em></td>
<td>None</td>
<td>Wrist, Ankle</td>
<td>X-ray, MRI, Biopsy, HPLC</td>
<td>CLARY, CIP, RFP</td>
<td>Yes</td>
<td>2 years</td>
</tr>
<tr>
<td>Wong KP et al</td>
<td>83/M</td>
<td><em>M. fortuitum</em></td>
<td>Diabetes</td>
<td>Ankle</td>
<td>DHT, HPLC</td>
<td>CLARY, DOX</td>
<td>Yes</td>
<td>12 months</td>
</tr>
<tr>
<td>Bhatt et al</td>
<td>50/F</td>
<td><em>M. kansasi</em></td>
<td>None</td>
<td>Elbow, Clavicle</td>
<td>X-ray, Culture, PCR</td>
<td>None</td>
<td>Yes</td>
<td>0 days*</td>
</tr>
<tr>
<td>Breda et al</td>
<td>3/F</td>
<td><em>MAC</em></td>
<td>Immunodeficiency</td>
<td>Femur</td>
<td></td>
<td>RFP, CLARY</td>
<td>Yes</td>
<td>6 months</td>
</tr>
<tr>
<td>Kadota et al</td>
<td>63/F</td>
<td><em>M. abscessus</em></td>
<td>None</td>
<td>Vertebra</td>
<td>MRI, Culture, DHT, PCR</td>
<td>LVFX, CLARY, AMK</td>
<td>Yes</td>
<td>2 years</td>
</tr>
<tr>
<td>Diaz et al</td>
<td>15/M</td>
<td><em>M. goodii</em></td>
<td>Operation</td>
<td>Femur</td>
<td>MRI, Culture, PCR</td>
<td>TMP/SMX, AMK, CIP</td>
<td>Yes</td>
<td>5 months</td>
</tr>
<tr>
<td>Dong et al</td>
<td>48/F</td>
<td><em>M. chelonae</em></td>
<td>None</td>
<td>Vertebra</td>
<td>MRI, NGS, Biopsy</td>
<td>LVFX, EMB, AMK</td>
<td>No</td>
<td>5 months</td>
</tr>
<tr>
<td>Mastroyannis et al</td>
<td>70/M</td>
<td><em>M. flavescens</em></td>
<td>Diabetes</td>
<td>Vertebra</td>
<td>MRI, Biopsy, Culture, Metacarpal</td>
<td>RFP, CIP</td>
<td>No</td>
<td>13 months</td>
</tr>
<tr>
<td>Harp et al</td>
<td>83/M</td>
<td><em>M. chelonae</em></td>
<td>Operation</td>
<td>Vertebra</td>
<td>MRI, Biopsy, Culture, Metacarpal</td>
<td>CLO, AZT</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Omori et al</td>
<td>74/M</td>
<td><em>M. abscessus</em></td>
<td>Immunosuppression</td>
<td>Vertebra</td>
<td>MRI, NAC, WGS</td>
<td>CLARY, AMK, IPM</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Garcia et al</td>
<td>44/M</td>
<td><em>MAC</em></td>
<td>Drug abuser</td>
<td>Vertebra</td>
<td>MRI, Culture, PCR</td>
<td>CLARY, AMK, FOX</td>
<td>No</td>
<td>6 months</td>
</tr>
<tr>
<td>Johnson et al</td>
<td>47/F</td>
<td><em>MAC</em></td>
<td>None</td>
<td>Clavicle, Fibula</td>
<td>X-ray, Culture, Biopsy, PCR</td>
<td>DAP, NAP</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Xu X et al</td>
<td>43/F</td>
<td><em>M. avium</em></td>
<td>None</td>
<td>Clavicle, Skull, Sternum</td>
<td>CT, Culture, PCR</td>
<td>CLARY, EMB, AMX</td>
<td>Yes</td>
<td>5 months</td>
</tr>
<tr>
<td>Maupin J et al</td>
<td>55/M</td>
<td><em>M. senegalense</em></td>
<td>Cataclasis</td>
<td>Tibia, Fibula</td>
<td>PCR</td>
<td>IPM, LZD, AZM</td>
<td>Yes</td>
<td>4 months</td>
</tr>
</tbody>
</table>

**Abbreviations:** NTM, non-tuberculous mycobacteria; HPLC, high-performance liquid chromatography; DHT, DNA hybridization technology; NGS, next-generation sequencing; NAC, nucleic acid chromatography; MAC, *Mycobacterium avium* complex; FOX, cefoxitin; CIP, ciprofloxacin; CLARY, clarithromycin; IPM, imipenem; LZD, linezolid; MXF, moxifloxacin; AZT, azithromycin; RFP, rifampicin; INH, isoniazid; PZD, pyrazinamide; VAN, vancomycin; AZM, azithromycin; MIN, minocycline; EMB, ethambutol; AMK, amikacin; AMX, amoxicillin; MEM, meropenem; DOX, doxycycline; LVFX, levofloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; CLO, clofazolamide; DAP, daptomycin; NAP, naproxen.

*Indicates that the patient died before the bacterial identification results were available.
Ciprofloxacin (23.8%), and rifampicin (23.8%). In general, individualized antimycobacterial chemotherapy was successful; most patients recovered well, and only 1 patient died before receiving medicine. However, the treatment duration was long, at a minimum of 5 months and a maximum of 2 years in our review (Table 1).

The transition of bacteria to cell wall-deficient L-forms in response to stress factors has been assumed to be a potential mechanism for the survival of microbes. Under unfavorable conditions, many bacterial species can develop a state called an L-form, which has lost the peptidoglycan cell wall. Therefore, L-forms are completely resistant to most antibiotics that work specifically on cell wall synthesis. L-form bacteria can persist in humans even under the action of antibiotics. NTM often change into L-forms after treatment, which leads to increased drug resistance, with some patients failing to recover despite years of treatment.

L-form bacteria can be induced by cell wall-targeting antibiotics and require a medium with high osmolality for survival and growth. Except for the cell wall, the pathogenic factors of L-forms are similar to those of the prototype bacteria. There have been sporadic reports of L-forms being involved in a wide range of often chronic or recurrent infections. L-forms of *S. aureus*, *Pseudomonas aeruginosa*, *Neisseria gonorrhoeae*, *Salmonella*, and *M. tuberculosis* have been reported. We compared the antibiotic sensitivity of bacterial prototypes and their L-forms.

Unlike the prototype bacteria, L-forms are resistant to a series of antibiotics acting on the cell wall, such as penicillins and cephalosporins. Therefore, for infections involving L-forms, we can select antibiotics that act on both the bacterial cell wall and plasma membrane, such as vancomycin and neomycin; antibiotics that act on the plasma membrane and interfere with protein synthesis, such as amikacin and gentamicin; and antibiotics that inhibit bacterial nucleic acid synthesis, such as ofloxacin and levofloxacin. L-forms can infect various parts of the human body and can revert to the prototype bacteria with cell walls during treatment. Therefore, we should adopt combined therapy, choosing antibiotics that target both the prototype bacteria and the L-form bacteria.

In our report, the patient underwent vacuum sealing drainage treatment, under epidural anesthesia. Short-term pus culture did not grow any pathogen, but acid-fast bacilli were initially observed on the smear. Reports indicate that under the action of anti-TB drugs such as ethambutol, the synthesis disorder of mycobacterial cell wall leads to the production of L-forms, which can survive longer than the classical forms under adverse conditions. Therefore, for osteomyelitis patients with a poor response to treatment, NTM and its L-forms should also be considered in addition to TB and MDR-TB infection.

The identification of the specific NTM species in the clinical specimen is crucial since the treatment regimens differ strikingly among different NTM strains. In the present case, we have found that liquid culture media grow NTM bacterial more rapidly than solid media, and pus samples need to be digested to better cultivate NTM and its L-form. Nevertheless, we still took 4 weeks to obtain the culture results. PCR-based sequencing has become the gold standard for the identification of mycobacterial species. In the absence of a microbial pathogen, we obtained an adequate amount of specimens and performed PCR assays, and finally identified the pathogen as *M. aubagnense*. On microscopy and electron microscope, we found spherical bacteria, and conducted a reversion test to confirm the existence of the L-form.

Currently, there are no consistent guidelines for the treatment of vertebral osteomyelitis caused by NTM because few clinical trials have an adequate number of patients to compare different therapeutic regimens. The appearance of L-form NTM lacking cell walls increased the difficulty of diagnosis and treatment in the present case. We chose rifampin (which inhibits bacterial DNA-dependent RNA polymerase), linezolid (which inhibits bacterial protein synthesis through binding to rRNA), ethambutol, prothionamide, isoniazid, and moxifloxacin (a fluoroquinolone) for combination therapy. We also performed surgical resection, drainage of the abscess, and provided VSD coverage for the wound, and continued highly active antiretroviral therapy. The patient recovered after 10 months of treatment. Our report describes the treatment recommendations for mainly *M. aubagnense* infection, but the optimal duration of antibiotic treatment remains unclear.
Conclusion
In conclusion, osteomyelitis caused by L-form NTM is unusual in clinical practice. Clinicians should be aware of the potential for this uncommon infection, so that they can avoid misdiagnosis or delayed diagnosis. This article is the first to report a case of refractory osteomyelitis caused by *M. aubagnense* and its L-form. We reiterate that L-form mycobacterial infection should be considered when acid-fast positive spheroids are found on microscopy, even if the mycobacterial culture is negative, because mycobacteria can transition into L-forms under the influence of long-term anti-TB drugs treatment. We can confirm the existence of L-forms through electron microscopy, reversion tests, and PCR assays. Extensive surgical debridement is key to eliminating the offending pathogen, and antimycobacterial therapy is also important. Among anti-NTM antibiotic drugs, rifampicin, protonamide, linezolid, and other drugs have obvious effects on L-form NTM.

Abbreviations
NTM, non-tuberculosis mycobacteria; HPLC, high-performance liquid chromatography; NGS, next-generation sequencing; DHT, DNA hybridization technology; WGS, whole genome sequencing; NAC, nucleic acid chromatography; MAC, *Mycobacterium avium* complex; FOX, cefoxitin; CIP, ciprofloxacin; CLARY, clarithromycin; IPM, imipenem; LZD, linezolid; MXF, moxifloxacin; AZT, azithromycin; RFP, rifampicin; INH, isoniazid; PZD, pyrazinamide; VAN, vancomycin; AZM, azithromycin; MIN, minocycline; EMB, ethambutol; AMK, amikacin; MEM, meropenem; DOX, doxycycline; LVFX, levofloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; CLO, clofazolamide; DAP, daptomycin; NAP, naproxen; AMX, amoxicillin.

Data Sharing Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval and Informed Consent
This case report was approved by the ethics committee of Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University. The patient provided written informed consent. The study was carried out in accordance with the principles of the Declaration of Helsinki. The first author vouches for the completeness and accuracy of the data and for the fidelity of the study to the protocol.

Consent for Publication
Signed consent was obtained for the publication of the case details from the patient.

Acknowledgments
We thank the patient who participated in this study for his cooperation.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure
The authors have no conflicts of interest to declare in this work.
References


